An observational study in Poststroke Hemiplegia, sponsored by Qingdao Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Qingdao Central Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.
Among the 613 studies in Stroke with a site in China, this one is the 171st largest by planned enrollment of the 180 observational ones that give a count, is one of 66 that started in 2026, is one of 181 observational ones, reaches primary completion later than 177 of the 262 other live ones, and was the 609th registered.
8,279 studies on the registry are indexed under Stroke; 2,066 are open to participants now.
Browse Stroke studies →242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in China
Ages 18–80 · Healthy volunteers
Beijing Pins Medical Co., Ltd · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 12–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,421 Stroke studies recruiting now, 698 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
613 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 72 · Phase 4 42
First in 2000; this study’s year is marked. 66 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 169 across the 432 interventional studies, 611 across the 180 observational. Of the 211 that completed or were terminated, 31 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 613 have an industry lead sponsor. The 10 most frequent:
Qingdao Central Hospital is the lead sponsor of 25 studies on the registry; 11 are open to participants now.
Qingdao Central Hospital has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
69 of the studies in Stroke with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976152Phase 3Fudan UniversityEffect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) | 2026-12 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07002476Phase 3Shanghai East HospitalEarly Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion | 2027-03-01 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
Add all 69 to your calendar (.ics) → With an account.
Among the 613 studies in Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effects of spinal cord stimulation (SCS) combined with brain-computer interface (BCI)-assisted rehabilitation on motor function in patients with post-stroke hemiplegia using multisource neurophysiological data. In this single-group study with repeated measurements, participants undergo four weeks of SCS combined with BCI-driven upper- and lower-limb rehabilitation. Immediate motor performance is compared between SCS ON and OFF conditions under standardized tasks. Changes in motor function and multisource neurophysiological and kinematic measures are also assessed before and after rehabilitation to characterize treatment responses and explore their relationships with clinical motor improvement.
This is a single-group study using a within-participant pre-post design with repeated measurements. The study enrolls patients with post-stroke hemiplegia who meet the clinical indications for spinal cord stimulation (SCS) surgery and require SCS treatment. Following preoperative baseline assessment, participants undergo SCS implantation based on clinical indications, followed by stimulation parameter adjustment, individualized brain-computer interface (BCI) model calibration, and rehabilitation device setup.
The study includes four weeks of SCS combined with BCI-assisted synchronized upper- and lower-limb active rehabilitation. The first week includes postoperative recovery, stimulation parameter adjustment, and early closed-loop training. During rehabilitation, the BCI system identifies motor intentions from electroencephalography (EEG) signals in real time and drives upper- and lower-limb rehabilitation robots to provide corresponding assisted movements, establishing a closed-loop process integrating motor intention, robotic assistance, and sensorimotor feedback. Training is planned for three to five sessions per week, with 45-60 minutes of effective training per session.
Repeated measurements under SCS ON and OFF conditions are performed to evaluate the immediate effects of stimulation. With BCI closed-loop tasks, robotic assistance settings, and movement requirements held constant, motor performance during affected upper-limb, lower-limb, and synchronized upper- and lower-limb tasks is compared between SCS OFF and ON conditions. At least one standardized ON/OFF comparison is conducted each week during the intervention period.
Assessments are conducted at the preoperative baseline (T0), postoperative immediate-effect assessment (T1), week-2 mid-intervention assessment (T2), week-4 endpoint assessment (T3), and follow-up (T4). Clinical motor function assessments and multisource data, including EEG, functional near-infrared spectroscopy, electromyography, electrodermal activity, upper- and lower-limb kinematics, and BCI control logs, are used to evaluate changes in motor function, cortical activity, muscle activation patterns, interlimb coordination, and BCI closed-loop performance. Relationships between objective measures and improvements in clinical motor function are also examined.
The study population consists of adults aged 18 to 75 years with imaging-confirmed ischemic or hemorrhagic stroke and unilateral hemiplegia. Participants must meet the clinical indications for spinal cord stimulation (SCS) implantation and be scheduled to undergo SCS surgery for clinical reasons. They must be clinically stable and able to complete brain-computer interface (BCI) calibration, synchronized upper- and lower-limb rehabilitation assessments, and multisource physiological data collection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive SCS combined with EEG-driven BCI-assisted synchronized upper- and lower-limb active rehabilitation. After baseline assessment, SCS implantation, and parameter adjustment, participants complete four weeks of training and weekly SCS ON/OFF comparisons under consistent BCI tasks and robotic assistance settings. Clinical motor outcomes, multisource neurophysiological signals, kinematics, and BCI control logs are collected
Device: Spinal Cord Stimulation (SCS) · Device: Brain-Computer Interface Active Rehabilitation System
An epidural SCS system is used, comprising stimulation electrodes, a pulse generator or external stimulator, a programming system, and an event recording system. The clinical team determines the stimulation target according to motor impairments, surgical safety, and the established treatment plan. Standardized SCS OFF and ON comparisons are performed under consistent BCI tasks and robotic assistance settings, with stimulation parameters, motor performance, and related physiological data recorded
The BCI active rehabilitation system identifies motor intention during imagery or attempted movement from real-time EEG signals and triggers corresponding assisted movements using upper- and lower-limb rehabilitation robots, forming a closed loop between motor intention, sensory feedback, and limb movement. Rehabilitation continues for four weeks, three to five times per week (preferably five), with 45-60 minutes of effective training per session. At least one standardized SCS ON/OFF comparison is performed weekly
Also known as: EEG-Driven BCI-Assisted Synchronized Upper- and Lower-Limb Active Rehabilitation
Difference in Immediate Motor Task Performance Between SCS ON and OFF Conditions
Motor performance during affected upper-limb, lower-limb, and synchronized upper- and lower-limb tasks is compared between SCS ON and OFF conditions, with BCI closed-loop mode and robotic assistance parameters kept consistent, to evaluate the immediate effects of SCS
Time frame: Intervention weeks 1-4 (T1-T3)
Change in Upper- and Lower-Extremity Fugl-Meyer Assessment Scores
The Fugl-Meyer Assessment (FMA) is used to evaluate changes in upper- and lower-extremity motor function separately before and after four weeks of combined rehabilitation
Time frame: Preoperative baseline (T0, 1-2 weeks before surgery) to the end of intervention week 4 (T3)
Pearson/Spearman Correlation Between Multisource Objective Measures and Clinical Motor Improvement
Pearson or Spearman correlation analysis will be performed to examine the correlation between multisource neurophysiological measures (EEG, fNIRS, EMG, electrodermal), kinematic parameters, and BCI closed-loop performance metrics, and the change in Fugl-Meyer Assessment (FMA) score, to identify objective features linked to the effects of combined rehabilitation.
Time frame: Preoperative baseline (T0, 1-2 weeks before surgery) to the end of intervention week 4 (T3)
Change in 10-Meter Walk Test Speed
Walking ability is assessed using the 10-Meter Walk Test.
Time frame: T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)
Change in Modified Ashworth Scale Scores
Changes in spasticity of the affected upper and lower limbs are assessed using the Modified Ashworth Scale
Time frame: T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)
Changes in Motor-Related EEG Features
Changes in movement-related EEG rhythms, movement-related cortical potentials, and motor intention decoding features are assessed
Time frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
Changes in Motor-Area fNIRS Hemodynamic Responses
Changes in motor-area hemodynamic responses during motor tasks are assessed using functional near-infrared spectroscopy (fNIRS)
Time frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
Changes in Upper- and Lower-Limb EMG Activity and Muscle Synergies
Changes in target-muscle activation, active contribution, abnormal muscle synergies, co-contraction, and interlimb temporal coupling are assessed using upper- and lower-limb electromyography (EMG)
Time frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
Changes in Electrodermal Responses and Stimulation Tolerability
Electrodermal responses and stimulation tolerability are evaluated using electrodermal signals and records of stimulation-related discomfort
Time frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), including assessments during the 4-week intervention period
Changes in Upper- and Lower-Limb Kinematics and Coordination
Changes in movement speed, smoothness, trajectory deviation, joint range of motion, gait or pedaling symmetry, and interlimb coordination are assessed
Time frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
BCI Decoding and Closed-Loop Control Performance
BCI performance is evaluated using decoding accuracy, valid trigger rate, false trigger rate, control latency, robotic task completion rate, assistance level, and online model stability
Time frame: From initial BCI calibration (T0, 1-2 weeks before surgery) to end of intervention week 4 (T3), with follow-up assessment at T4 (4 weeks after SCS electrode removal)
Safety, Training Completion, and Data Acquisition Quality
SCS-, BCI-, and robotic device-related adverse events, training completion, device tolerability, and the completeness and quality of synchronized upper- and lower-limb data acquisition are recorded
Time frame: During the 4-week intervention after SCS implantation, with final assessment at T4 (4 weeks after SCS electrode removal)
Change in Berg Balance Scale Score
Balance function is assessed using the Berg Balance Scale.
Time frame: T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)
Plan to share: No — Individual participant data will not be shared with external researchers. Study data will be used for analyses within this research project. Study findings will be reported in aggregate form while protecting participant privacy
Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 11 months is below that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qingdao Central Hospital